Consistent with our earlier reported observations, enhanced tumor cell death was validated by the significantly increased Bax/Bcl2 ratio in tumor tissue of Myr-NE xenografts, compared to Myricetin treated xenografts (Figure 5F) (13). The gene discussed is BAX; the disease is neoplasm.